Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript

AJ Bergmann: Yes. Thanks, Alan. Nice to hear from you. I mean, obviously, bringing in nondilutive capital is a big focus for us, as you heard Linda articulate, both from a potential in our approach to vaccinology as well as the next steps, which is targeted therapeutics. Where exactly would we like to deploy it? I mean if I had my wish list, it would be great to use that nondilutive capital to move into these types of new indications that we’re hinting at here, whether it’s new neuromuscular targets, potentially using the exosome as a targeted vehicle, that would be my wish list. And taking those nondilutive capital dollars in the door is a big area that we’re putting a lot of energy in. I don’t know if Linda want to articulate anything else?

Linda Marban: Yes. So cash is king, as you are in product development mode. And so, what we would definitely do is use it in a laser-focused targeted way to move our programs forward. So CAP-1002 is at the front of the line right now. All major dollars being spent or being spent on getting CAP-1002 approved and then the few dollars left over, go towards the exosome program as we move that forward. If the dollars come in and are specifically requested to build a program, we would obviously work on that. For instance, if there was a deal where they wanted to build engineered exosome, that’s where a good proportion of those dollars would go. So to that end, we are focusing on what we need to do, AJ, maintain a very tight ship in terms of managing our resources, and that explains why we’ve been able to stay alive through some pretty difficult time.

Unidentified Participant: Well, I look forward in the intermediate future, Linda, to walk in your office. The future looks bright for both of us and I’m pleased this is what I hear. Yes.

Linda Marban: That’s wonderful news. The future is bright for Capricor. But if the future is bright for you, that’s great news, Alan. So let’s see each other soon.

Unidentified Participant: Thank you. Looking forward to it.

AJ Bergmann: Take care Alan.

Operator: [Operator Instructions] There seems to be no further questions at this time. I’d now like to turn the call back over to Capricor management for any closing remarks.

Linda Marban: Thank you. Overall, I am confident that the company’s upcoming catalysts provide a solid foundation for execution and value creation. We remain focused on driving our late-stage clinical development program forward for CAP-1002 and DMD. Before we conclude today’s call, I want to extend my sincere appreciation to the clinicians, patients and their families who are working with us to bring CAP-1002 closer to potential approval. Again, thanks to everyone who joined us this afternoon, and now you may disconnect your lines.